Drug Search Results
Using advanced filters...
Advanced Search [+]

ABSK121-NX

Alternative Names: ABSK121-NX, ABSK121NX
Clinical Status: Active
Latest Update: 2023-06-28
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: FGFR2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Abbisko
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ABSK121-NX

Countries in Clinic: China, United States

Active Clinical Trial Count: 2

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

ABSK121-NX-101

P1

Recruiting

Oncology Solid Tumor Unspecified

2025-03-15

21%

2023-06-30

CTR20231152

P1

Recruiting

Oncology Solid Tumor Unspecified

None

2025-04-29

Patient Enrollment|Start Date|Treatments|Trial Status

Recent News Events

Date

Type

Title